MétaCan
Menu
← Back to cohort
Record W3184904659 · doi:10.1158/0008-5472.can-21-0774

Acquired <i>RAD51C</i> Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma

2021· article· en· W3184904659 on OpenAlexfundno aff
Ksenija Nesic, Olga Kondrashova, Rachel M. Hurley, Cordelia D. McGehee, Cassandra J. Vandenberg, Gwo‐Yaw Ho, Elizabeth Lieschke, Genevieve Dall, Nirashaa Bound, Kristy Shield‐Artin, Marc R. Radke, Ashan Musafer, Zi Qing Chai, Mohammad Reza Eftekhariyan Ghamsari, Maria I. Harrell, Damien Kee, Inger Olesen, Orla McNally, Nadia Traficante, Australian Ovarian Cancer Study, Anna DeFazio, David D.L. Bowtell, Elizabeth M. Swisher, S. John Weroha, Kátia Nones, Nicola Waddell, Scott H. Kaufmann, Alexander Dobrovic, Matthew J. Wakefield, Clare L. Scott

Bibliographic record

VenueCancer Research · 2021
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsnot available
FundersNational Institute of General Medical SciencesCancer Council TasmaniaCancer Council VictoriaCancer Council South AustraliaVictorian Cancer AgencyEntertainment Industry FoundationStand Up To CancerMedical Research CouncilPeter MacCallum FoundationAstraZeneca AustraliaMedical Research and Materiel CommandEisaiOvarian Cancer Research FundCancer AustraliaNational Cancer InstituteAustralian Cancer Research FoundationMayo Foundation for Medical Education and ResearchState Government of VictoriaAustralian GovernmentCancer Council NSWOvarian Cancer AustraliaNational Breast Cancer FoundationClovis OncologySierra OncologyNational Ovarian Cancer CoalitionAmerican Association for Cancer ResearchNational Health and Medical Research CouncilCancer Research InstituteAstraZenecaOvarian Cancer Research Fund AllianceNational Institutes of Health
KeywordsSerous fluidPARP inhibitorOvarian carcinomaMethylationCancer researchMedicineOvarian cancerOncologyInternal medicineBiologyPoly ADP ribose polymeraseCancerGeneGeneticsPolymerase

Abstract

fetched live from OpenAlex

ABSTRACT While loss of BRCA1 promoter methylation has been shown to cause PARP inhibitor (PARPi) resistance in high-grade serous ovarian carcinoma (HGSC), the impacts of RAD51C methylation (me RAD51C ) remain unresolved. In this study, three PARPi-responsive HGSC patient-derived xenografts (PDX) with RAD51C gene silencing and homologous recombination deficiency were found to have either homogeneous or heterogeneous patterns of me RAD51C . PDX could lose me RAD51C following PARPi treatment (rucaparib/niraparib), where a single unmethylated RAD51C copy was sufficient to drive PARPi-resistance. Genomic profiling revealed this resistance was acquired independently in two distinct PDX lineages. Furthermore, we describe a patient sample where 1/3 RAD51C gene copies lost methylation following neoadjuvant chemotherapy. We show me RAD51C is a positive predictive biomarker for PARPi response and should be screened for routinely in patients. However, methylation loss in a single gene copy is sufficient to cause PARPi resistance and should be carefully assessed in previously treated patients considering PARPi therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.093
GPT teacher head0.402
Teacher spread0.309 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations86
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicPARP inhibition in cancer therapy→French-language works237,207→